Development of metronidazole-resistant lines of Blastocystis sp. - Aix-Marseille Université Access content directly
Journal Articles Parasitology Research Year : 2012

Development of metronidazole-resistant lines of Blastocystis sp.

L. A. Dunn
  • Function : Author
K. S. W. Tan
  • Function : Author
T. Juspin
  • Function : Author
M. D. Crozet
  • Function : Author
P. Upcroft
  • Function : Author
J. A. Upcroft
  • Function : Author


Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTRR) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTRR lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTRR lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTRR lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.

Dates and versions

hal-01460365 , version 1 (07-02-2017)



L. A. Dunn, K. S. W. Tan, P. Vanelle, T. Juspin, M. D. Crozet, et al.. Development of metronidazole-resistant lines of Blastocystis sp.. Parasitology Research, 2012, 111 (1), pp.441--450. ⟨10.1007/s00436-012-2860-7⟩. ⟨hal-01460365⟩


22 View
0 Download



Gmail Facebook X LinkedIn More